IGFBP-3: The Binding Protein Behind Your IGF-1 Result

IGFBP-3 carries most of the IGF-1 in the bloodstream and shapes how an IGF-1 result should be read. This article explains what the marker measures, why it moves with nutrition, liver and thyroid status, and why physicians sometimes order it alongside IGF-1 on a GH-axis panel.

By The Protocols Company Research Desk

Most people who have had a growth hormone axis panel know their IGF-1 number. Far fewer have looked at the line underneath it. IGFBP-3, or insulin-like growth factor binding protein 3, is the carrier protein that holds the overwhelming majority of IGF-1 in the bloodstream, and it shapes how an IGF-1 result should be read. Understanding what it is, why it moves, and why physicians sometimes order it alongside IGF-1 makes a GH-axis blood panel considerably more informative.

What IGFBP-3 is and what it does

IGF-1 does not travel through the blood on its own. Around three quarters or more of circulating IGF-1 is bound in a three-part complex made up of IGF-1, IGFBP-3 and a third protein called the acid-labile subunit. This complex is too large to leave the circulation easily, which is why IGF-1 bound to IGFBP-3 remains in the blood for many hours, whereas unbound IGF-1 is cleared within minutes. IGFBP-3 acts as both a reservoir and a regulator, releasing IGF-1 gradually and limiting how much is available to tissues at any one time.

Like IGF-1, IGFBP-3 is produced mainly by the liver under the influence of growth hormone. Because GH is released in pulses and a random GH measurement tells a physician very little, both IGF-1 and IGFBP-3 are used as more stable, integrated reflections of GH output over the preceding days. IGFBP-3 shows relatively little hour-to-hour variation and does not require fasting, which is one reason it has found a place in endocrine assessment.

An IGF-1 result is a number about a passenger. IGFBP-3 is a number about the vehicle it travels in.

Why physicians order it alongside IGF-1

In clinical endocrinology IGFBP-3 has been studied most thoroughly in the assessment of growth hormone deficiency, particularly in children, where it is measured together with IGF-1 before any stimulation testing is considered. In adults its diagnostic value on its own is more limited, and most endocrine guidance regards it as a supporting marker rather than a primary one. Its value lies in context. A low IGF-1 with a normal IGFBP-3 points in a different direction from a low IGF-1 with a low IGFBP-3, and the pairing helps a physician decide whether the picture is about GH output, about the liver, or about something else entirely.

  • Nutrition: both IGF-1 and IGFBP-3 fall with inadequate energy or protein intake, and IGF-1 tends to fall first and further.
  • Liver function: because both proteins are made largely in the liver, chronic liver disease lowers them regardless of GH status.
  • Thyroid status: untreated hypothyroidism is associated with lower IGF-1 and IGFBP-3, which is one reason thyroid markers sit on the same panel.
  • Insulin and glucose control: insulin influences hepatic production of both proteins, and poorly controlled diabetes can shift the ratio between them.
  • Age: both markers peak in adolescence and decline steadily through adult life, so results must be read against age-specific reference ranges.

Some researchers have proposed the IGF-1 to IGFBP-3 molar ratio as an approximate index of how much IGF-1 is free rather than bound. The idea is attractive, but the ratio is not standardised across laboratories, and different assays produce different absolute numbers. Most physicians treat it as an additional piece of information to be weighed, not as a standalone diagnostic.

What this means on a GH-axis peptide panel

Research into growth hormone secretagogues and GHRH analogues has typically tracked IGF-1 as the main biochemical endpoint, and several published studies have reported IGFBP-3 alongside it. Because IGFBP-3 responds to GH more slowly and less dramatically than IGF-1, it tends to confirm a trend rather than reveal one. An independent DHA-licensed physician reviewing a baseline panel may include IGFBP-3 to establish a reference point, to help interpret an unexpected IGF-1 value, or to check that a change in IGF-1 reflects the GH axis rather than a change in nutrition, liver function or thyroid status.

IGFBP-3 also has a research life of its own. Laboratory studies have examined actions that appear independent of IGF-1, including effects on cell growth and programmed cell death, and epidemiological work has looked at how circulating levels relate to long-term health outcomes. Findings across these studies are mixed and in some cases contradictory, and none of this research translates into anything a patient should act on directly. It does, however, explain why a physician may be reluctant to see IGF-1 pushed high without knowing what its binding protein is doing.

Clinical nuance: when the two markers disagree

Proteases in the blood can cleave IGFBP-3 into fragments that bind IGF-1 less tightly. This happens during pregnancy, acute illness, after surgery and in some chronic inflammatory states, and it means a total IGFBP-3 measurement can look normal while the functional binding capacity has changed. It is one of several reasons a single result is rarely interpreted in isolation. A physician will usually want IGF-1, IGFBP-3, liver enzymes, thyroid function, fasting glucose and a measure of inflammation on the same draw, and will repeat the panel after a reasonable interval rather than acting on one set of numbers.

Whether any protocol is appropriate is a decision for an independent DHA-licensed physician. Read more on the IGF-1 LR3 page.

If you want to understand whether any of this is relevant to you, an independent DHA-licensed physician can review your case. Take the two-minute quiz at /find-my-stack or book a physician consultation at /book (AED 300 deposit, credited to your first order).

The Protocols Company